Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in CML-CP
NCT03578367Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2018
- Primary completion
- Nov 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 15
01
Overview
A Phase 2 trial of asciminib in chronic myeloid leukemia (CML), sponsored by Novartis. Started Nov 2018; status: completed.
02
Drugs
asciminib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03578367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03578367.